Autologous stromal vascular fraction therapy for rheumatoid arthritis

Rationale and clinical safety

Jorge Paz Rodriguez, Michael P. Murphy, Soonjun Hong, Marialaura Madrigal, Keith L. March, Boris Minev, Robert J. Harman, Chien Shing Chen, Ruben Berrocal Timmons, Annette M. Marleau, Neil H. Riordan

Research output: Contribution to journalArticle

Abstract

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Original languageEnglish
Pages (from-to)5
Number of pages1
JournalInternational Archives of Medicine
DOIs
StateAccepted/In press - Feb 8 2012
Externally publishedYes

Fingerprint

Blood Vessels
Rheumatoid Arthritis
Safety
Biological Therapy
Veterinary Medicine
Therapeutics
Clinical Protocols
Cell- and Tissue-Based Therapy
Stem Cells
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paz Rodriguez, J., Murphy, M. P., Hong, S., Madrigal, M., March, K. L., Minev, B., ... Riordan, N. H. (Accepted/In press). Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety. International Archives of Medicine, 5. https://doi.org/10.1186/1755-7682-5-5

Autologous stromal vascular fraction therapy for rheumatoid arthritis : Rationale and clinical safety. / Paz Rodriguez, Jorge; Murphy, Michael P.; Hong, Soonjun; Madrigal, Marialaura; March, Keith L.; Minev, Boris; Harman, Robert J.; Chen, Chien Shing; Timmons, Ruben Berrocal; Marleau, Annette M.; Riordan, Neil H.

In: International Archives of Medicine, 08.02.2012, p. 5.

Research output: Contribution to journalArticle

Paz Rodriguez, J, Murphy, MP, Hong, S, Madrigal, M, March, KL, Minev, B, Harman, RJ, Chen, CS, Timmons, RB, Marleau, AM & Riordan, NH 2012, 'Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety', International Archives of Medicine, pp. 5. https://doi.org/10.1186/1755-7682-5-5
Paz Rodriguez, Jorge ; Murphy, Michael P. ; Hong, Soonjun ; Madrigal, Marialaura ; March, Keith L. ; Minev, Boris ; Harman, Robert J. ; Chen, Chien Shing ; Timmons, Ruben Berrocal ; Marleau, Annette M. ; Riordan, Neil H. / Autologous stromal vascular fraction therapy for rheumatoid arthritis : Rationale and clinical safety. In: International Archives of Medicine. 2012 ; pp. 5.
@article{58fff0a516374262bc8a83708cc3bad6,
title = "Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety",
abstract = "Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50{\%} of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80{\%} improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.",
author = "{Paz Rodriguez}, Jorge and Murphy, {Michael P.} and Soonjun Hong and Marialaura Madrigal and March, {Keith L.} and Boris Minev and Harman, {Robert J.} and Chen, {Chien Shing} and Timmons, {Ruben Berrocal} and Marleau, {Annette M.} and Riordan, {Neil H.}",
year = "2012",
month = "2",
day = "8",
doi = "10.1186/1755-7682-5-5",
language = "English",
pages = "5",
journal = "International Archives of Medicine",
issn = "1755-7682",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Autologous stromal vascular fraction therapy for rheumatoid arthritis

T2 - Rationale and clinical safety

AU - Paz Rodriguez, Jorge

AU - Murphy, Michael P.

AU - Hong, Soonjun

AU - Madrigal, Marialaura

AU - March, Keith L.

AU - Minev, Boris

AU - Harman, Robert J.

AU - Chen, Chien Shing

AU - Timmons, Ruben Berrocal

AU - Marleau, Annette M.

AU - Riordan, Neil H.

PY - 2012/2/8

Y1 - 2012/2/8

N2 - Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

AB - Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

UR - http://www.scopus.com/inward/record.url?scp=84856610861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856610861&partnerID=8YFLogxK

U2 - 10.1186/1755-7682-5-5

DO - 10.1186/1755-7682-5-5

M3 - Article

SP - 5

JO - International Archives of Medicine

JF - International Archives of Medicine

SN - 1755-7682

ER -